Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome

Amarin Corporation plc (NASDAQ: AMRN) announced a new analysis from the Vascepa/Vazkepa (icosapent ethyl) cardiovascular outcomes REDUCE-IT study.

The study exhibited the effectiveness of Vascepa/Vazkepa in patients with the recent acute coronary syndrome.